PU.1-W215G LZRS
(Plasmid
#44635)
-
Depositing Lab
-
Publication
-
Sequence Information
Full plasmid sequence is not available for this item.
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 44635 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backboneLZRS
- Backbone size w/o insert (bp) 12443
- Total vector size (bp) 13300
-
Vector typeMammalian Expression, Retroviral
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature30°C
-
Growth Strain(s)Stbl3
-
Growth instructionsvery slow growing--allow extra time to propagate.
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert namePU.1 W215G
-
Alt nameSFFV proviral integration 1
-
SpeciesM. musculus (mouse)
-
Insert Size (bp)839
-
Mutation215 mutation (W to G)
-
Entrez GeneSpi1 (a.k.a. Dis-1, Dis1, PU.1, Sfpi-1, Sfpi1, Spi-1, Tcfpu1, Tfpu.1)
-
Tags
/ Fusion Proteins
- IRES (C terminal on backbone)
- EGFP (C terminal on backbone)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site EcoRI (not destroyed)
- 3′ cloning site NotI (not destroyed)
- 5′ sequencing primer LZRS-F
- 3′ sequencing primer EGFP-N (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Mouse PU.1 coding sequence with 215 mutation (W to G) that abolishes DNA binding. Subcloned from LZRS PU.1-WT (Addgene plasmid #34835).
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
PU.1-W215G LZRS was a gift from Ellen Rothenberg (Addgene plasmid # 44635 ; http://n2t.net/addgene:44635 ; RRID:Addgene_44635) -
For your References section:
Constitutive expression of PU.1 in fetal hematopoietic progenitors blocks T cell development at the pro-T cell stage. Anderson MK, Weiss AH, Hernandez-Hoyos G, Dionne CJ, Rothenberg EV. Immunity. 2002 Feb;16(2):285-96. 10.1016/S1074-7613(02)00277-7 PubMed 11869688